Key result
Targeted kinase inhibitors carry significant vascular and metabolic toxicities requiring proactive screening and management.
Why the study?
Kinase inhibitors used in cancer therapy have important cardiovascular and metabolic sequelae due to their roles in the cardiovascular system and metabolic homeostasis.
This review highlights the cardiovascular and metabolic toxicities of kinase inhibitors and proposes strategies for prevention, screening, and management in cardio-oncology.
Novel targeted cancer therapies, especially kinase inhibitors, have revolutionized the treatment of many cancers and have dramatically improved the survival of several types of malignancies. Because kinases not only are important in cancer development and progression, but also play a critical role in the cardiovascular (CV) system and metabolic homeostasis, important CV and metabolic sequelae have been associated with several types of kinase inhibitors. This paper reviews the incidences and highlights potential mechanisms of vascular and metabolic perturbations associated with 3 classes of commonly used kinase inhibitors that target the vascular endothelial growth factor signaling pathway, the ABL kinase, and the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway. We propose preventive, screening, monitoring, and management strategies for CV care of patients treated with these novel agents.
No takes yet. Share an insight, caveat, or question.
Li et al. (2015) conducted a review in Cancer. Novel targeted cancer therapies (kinase inhibitors) was evaluated on Vascular and metabolic perturbations. Novel targeted cancer therapies, particularly kinase inhibitors, are associated with significant cardiovascular and metabolic sequelae, requiring specific preventive, screening, and management strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: